Tucker R M, Haq Y, Denning D W, Stevens D A
Department of Medicine, Santa Clara Valley Medical Center, California Institute for Medical Research, San Jose 95128.
J Antimicrob Chemother. 1990 Oct;26(4):561-6. doi: 10.1093/jac/26.4.561.
Itraconazole was administered at doses of 50-400 mg/day to 189 patients with a variety of systemic mycoses for a median of five months. Adverse reactions possibly due to itraconazole were seen in 74 patients (39%). Mild gastrointestinal reactions were most common; other reactions including hypertriglyceridaemia, hypokalaemia and liver enzyme elevations occurred less frequently. No fatal reactions have been noted and toxicity has rarely led to a discontinuation of therapy. Chronic therapy with itraconazole appears well tolerated by the majority of patients.
对189例患有各种系统性霉菌病的患者给予伊曲康唑，剂量为50 - 400毫克/天，中位治疗时间为五个月。74例患者（39%）出现了可能由伊曲康唑引起的不良反应。轻度胃肠道反应最为常见；其他反应包括高甘油三酯血症、低钾血症和肝酶升高，发生频率较低。未观察到致命反应，毒性也很少导致治疗中断。大多数患者对伊曲康唑的长期治疗耐受性良好。
